Pioneering the future: CRISPR-Cas9 gene therapy for hereditary hemorrhagic telangiectasia
Eur J Intern Med
.
2024 Sep:127:140-141.
doi: 10.1016/j.ejim.2024.06.012.
Epub 2024 Jun 15.
Authors
Michael James
1
,
Viren S Sehgal
2
Affiliations
1
CUNY School of Medicine, Townsend Harris Hall, 160 Convent Avenue, New York, NY 10031, USA. Electronic address:
[email protected]
.
2
CUNY School of Medicine, Townsend Harris Hall, 160 Convent Avenue, New York, NY 10031, USA.
PMID:
38879351
DOI:
10.1016/j.ejim.2024.06.012
No abstract available
Publication types
Letter
MeSH terms
CRISPR-Cas Systems*
Gene Editing / methods
Genetic Therapy* / methods
Humans
Telangiectasia, Hereditary Hemorrhagic* / genetics
Telangiectasia, Hereditary Hemorrhagic* / therapy